The influence of KRAS and BRAF mutations on the efficacy of cetuximab‐based first‐line therapy of metastatic colorectal cancer: An analysis of the AIO KRK‐0104‐trial
暂无分享,去创建一个
V. Heinemann | J. Neumann | T. Kirchner | A. Jung | R. Laubender | S. Stintzing | S. Boeck | D. Modest | C. Giessen | C. Schulz | M. Haas | N. Moosmann